Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application

Molecular Pharmacology

Volumn 62, Issue 4, 2002, Pages 795-805

  Bonifácio, Maria João ^a   Archer, Margarida ^b,c   Rodrigues, Maria L ^b,c   Matias, Pedro M ^b   Learmonth, David A ^a   Carrondo, Maria Arménia ^b   Soares da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DIHYDROXY 5 NITROPHENYL) 3 (N 3' TRIFLUOROMETHYLPHENYL)PIPERAZINE 1 PROPANONE; ADRENALIN; BIA 3 335; CATECHOL; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; METADRENALIN; NEUROTRANSMITTER; PIPERAZINE DERIVATIVE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG INACTIVATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; IC 50; LIVER; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ANIMALS; BINDING SITES; CATECHOL O-METHYLTRANSFERASE; CRYSTALLIZATION; ENZYME INHIBITORS; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIPERAZINES; SUBSTRATE SPECIFICITY;

EID: 0036784071     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.4.795     Document Type: Article

References (60)

1. Bonifácio MJ, Vieira-Coelho MA, Borges N, and Soares-da-Silva P (2000) Kinetics of rat brain and liver solubilized membrane-bound catechol-O-methyltransferase. Arch Biochem Biophys 384:361-367.
2. Bonifácio MJ, Vieira-Coelho MA, and Soares-da-Silva P (2001) Expression and characterization of rat soluble catechol-O-methyltransferase fusion protein. Protein Expr Purif 23:106-112.
3. Bonifati V and Meco G (1999) New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 81:1-36.
4. Borges N, Vieira-Coelho MA, Parada A, and Soares-da-Silva P (1997) Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 282:812-817.
5. Brevitt SE and Tan EW (1997) Synthesis and in vitro evaluation of two progressive series of bifunctional polyhydroxybenzamide catechol-O-methyltransferase inhibitors. J Med Chem 40:2035-2039.
6. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr Sect D Biol Crystallogr 54:905-921.
7. Cha S (1975) Tight binding inhibitors-I. Kinetic behavior. Biochem Pharmacol 24:2177-2185.
8. 18F]Ro41-0960. Life Sci 58:195-208.
9. Fauman E, Blumenthal RM, and Cheng X (1999) Structure and evolution of AdoMet-dependent methyltransferases, in S-Adenosylmethionine-Dependent Methyltransferases: Structures and Functions (Cheng X and Blumenthal RM eds) pp 1-38, World Scientific, River Edge, NJ.
10. Gasparini M, Fabrizio E, Bonifati V, and Meco G (1997) Cognitive improvement during Tolcapone treatment in Parkinson's disease. J Neural Transm 104:887-894.
11. Holm L and Sander C (1993) Protein structure comparison by alignment of distance matrices. J Mol Biol 233:123-138.
12. Karhunen T, Tilgmann C, Ulmanen I, Julkunen I, and Panula P (1994) Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 42:1079-1090.
13. Kraulis (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 23:946-950.
14. Lautala P, Ulmanen I, and Taskinen J (2001) Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 59:393-402.
15. Learmonth DA and Soares-da-Silva P (2002) inventors, Portela & Ca., S.A., assignee. Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them. Patent Cooperation Treaty patent WO 01/98251 A1. 2001 Dec 27.
16. Lerner C, Ruf A, Gramlich V, Masjost B, Zürcher G, Jakob-Roetne R, Borroni E, and Diederich F (2001) X-ray crystal structure of a bisubstrate inhibitor bound to enzyme catechol-O-methyltransferase: a dramatic effect of inhibitor preorganization on a binding affinity. Angew Chem Int Ed 40:4040-4042.
17. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, and Taskinen J (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
18. Lundström K, Salminen M, Jalanko A, Savolainen R, and Ulmanen I (1991) Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 10:181-189.
19. Lundström K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, and Ulmanen I (1995) Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta 1251:1-10.
20. Männistö PT and Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
21. Männistö PT and Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10:54-56.
22. Männistö PT and Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66:317-323.
23. Männistö PT, Kaakkola S, Nissinen E, Linden IB, and Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43:1465-1471.
24. Männistö PT, Lang A, Rauhala P, and Vasar E (1995) Beneficial effects of coadministration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur J Pharmacol 274:229-233.
25. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C, and Kaakkola S (1992) Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39:291-350.
26. Masjost B, Ballmer P, Borroni E, Zürcher G, Winkler FK, Jakob-Roetne R, and Diederich F (2000) Structure-based design, synthesis and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry 6:971-982.
27. Merrit E and Murphy MEP (1994) Raster3D Version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr Sect D Biol Crystallogr 50:869-873.
28. Moreau J-L, Borgulya J, Jenck F, and Martin JR (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 5:344-350.
29. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochem Biophys Acta 185:269-286.
30. Nicholls A, Bharadwaj R, and Honig B (1993) GRASP: graphical representation and analysis of surface properties. Biophys J 64:A166.
31. Ovaska M and Yliniemelä A (1998) A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols. J Comput Aided Mol Des 12:301-307.
32. Paetzel M and Dalbey RE (1997) Catalytic hydroxyl/amine dyads within serine proteases. Trends Biochem Sci 22:28-31.
33. Paetzel M, Strynadka NC, Tschantz WR, Casareno R, Bullinger PR, and Dalbey RE (1997) Use of site-directed chemical modification to study an essential lysine in Escherichia coli leader peptidase. J Biol Chem 272:9994-10003.
34. Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, and Soares-da-Silva P (2001) BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. Eur J Pharmacol 420:27-32.
35. Parada A and Soares-da-Silva P (2000a) BIA 3-202 does not potentiate amphetamine-induced dopaminergic hyperactivity (Abstract). Br J Pharmacol 131:50P.
36. Parada A and Soares-da-Silva P (2000b) BIA 3-202 does not potentiate locomotor hyperactivity during increased dopaminergic stimulation (Abstract). Br J Pharmacol 131:49P.
37. Perez RA, Fernandez-Alvarez E, Nieto O, and Piedrafita FJ (1992) Dihydroxynitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: synthesis and biological activity as catechol-O-methyltransferase inhibitors. J Med Chem 35:4584-4588.
38. Perez RA, Fernandez-Alvarez E, Nieto O, and Piedrafita FJ (1994) Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone. J Enzyme Inhib 8:123-131.
39. Piedrafita FJ, Elorriaga C, Fernandez-Alvarez E, and Nieto O (1990) Inhibition of catechol-O-methyltransferase by N-(3,4-dihydroxyphenyl)maleimide. J Enzyme Inhib 4:43-50.
40. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, and Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the "wearing-off' phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49:1066-1071.
41. Rinne UK, Larsen JP, Siden A, and Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309-1314.
42. Rivett AJ, Francis A, and Roth JA (1983) Localization of membrane-bound catechol-O-methyltransferase. J Neurochem 40:1494-1496.
43. Rodrigues ML, Archer M, Bonifacio MJ, Soares-da-Silva P, and Carrondo MA (2001) Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its cosubstrate and an inhibitor. Acta Crystallogr Sect D Biol Crystallogr 57:906-908.
44. Roussel A and Cambilau C (1989) Silicon Graphics Geometry Partner Directory, Silicon Graphics, Mountain View, CA.
45. Salminen M, Lundström K, Tilgmann C, Savolainen R, Kalkkinen N, and Ulmanen I (1990) Molecular cloning and characterization of rat liver catechol-O-methyl-transferase. Gene 93:241-247.
46. Schluckebier G, O'Gara M, Saenger W, and Cheng X (1995) Universal catalytic domain structure of AdoMet-dependent methyltransferases. J Mol Biol 247:16-20.
47. Schultz E and Nissinen E (1989) Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 38:3953-3956.
48. Sheldrick GM (1997) Patterson superposition and ab initio phasing. Methods Enzymol 276:628-641.
49. Tenhunen J, Salminen M, Jalanko A, Ukkonen S, and Ulmanen I (1993) Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol 12:253-263.
50. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, and Ulmanen I (1994) Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223:1049-1059.
51. Tenhunen J and Ulmanen I (1993) Production of rat soluble and membrane-bound catechol O-methyltransferase forms from bifunctional mRNAs. Biochem J 296:595-600.
52. Toney MD and Kirsch JF (1989) Direct Bronsted analysis of the restoration of activity to a mutant enzyme by exogenous amines. Science (Wash DC) 243:1485-1488.
53. Vidgren J and Ovaska M (1997) Structural aspects in the inhibitor design of catechol O-methyltransferase, in Structure-Based Drug Design (Veerapandian P ed) pp 343-363, Marcel Dekker, Inc., New York.
54. Vidgren J, Ovaska M, Tenhunen J, Tilgmann C, Lotta T, and Männistö PT (1999) Catechol O-methyltransferase, in S-Adenosylmethionine-Dependent Methyltransferases: Structures and Functions (Cheng X and Blumenthal RM eds) pp 55-91, World Scientific Publishing, River Edge, NJ.
55. Vidgren J, Svensson LA, and Liljas A (1994) Crystal structure of catechol O-methyltransferase. Nature (Lond) 368:354-358.
56. Vieira-Coelho MA and Soares-da-Silva P (1999) Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821:69-78.
57. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, and Pedder S (1997) Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49:665-671.
58. Williams JW and Morrison JF (1979) The kinetics of reversible tight-binding inhibition. Methods Enzymol 63:437-467.
59. Zheng YJ and Bruice TC (1997) A theoretical examination of the factors controlling the catalytic efficiency of a transmethylation enzyme - catechol O-methyltransferase. J Am Chem Soc 119:8137-8145.
60. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, and Da Prada M (1990) Ro 40-7592, a novel, very potent and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 53:497-503.